(Q38150110)

29 August 2017

Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys (English)

1 reference

systemic lupus erythematosus

29 August 2017

1 reference

1 reference

2

Joan T Merrill

1 reference

29 August 2017

Aikaterini Thanou

1

1 reference

PubMed ID

24100460

29 August 2017

language of work or name

English

0 references

publication date

8 October 2013

1 reference

Nature Reviews Rheumatology

29 August 2017

1 reference

29 August 2017

10

1 reference

29 August 2017

1

1 reference

29 August 2017

23-34

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2013.145

29 August 2017

0 references

cites work

Treatment of systemic lupus erythematosus: new advances in targeted therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Interferon alpha as a primary pathogenic factor in human lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

The rationale for BAFF inhibition in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Top 10 things to know about lupus activity measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Recent insights into the genetic basis of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Gene-function studies in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

The role of defective clearance of apoptotic cells in systemic autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Taming lupus-a new understanding of pathogenesis is leading to clinical advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Lupus neutrophils: 'NET' gain in understanding lupus pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Protective Roles of Natural IgM Antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Autoantibodies and common viral illnesses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Prevalence of antinuclear antibodies in 3 groups of healthy individuals: blood donors, hospital personnel, and relatives of patients with autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Not always the bad guys: B cells as regulators of autoimmune pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

B cell biomarkers of rituximab responses in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Novel evidence-based systemic lupus erythematosus responder index

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Calcium signaling in systemic lupus erythematosus T cells: a treatment target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

T cells as therapeutic targets in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Laquinimod in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Sphingosine-1-phosphate and immune regulation: trafficking and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Fingolimod therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Peptide-based approaches to treat lupus and other autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Pathogenesis of ankylosing spondylitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Therapeutic blockade of TNF in patients with SLE-promising or crazy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

The future of CD20 monoclonal antibody therapy in B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Targeted tumor necrosis factor receptor I preligand assembly domain improves skin lesions in MRL/lpr mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

A meta-analysis of randomized controlled trials comparing tacrolimus with intravenous cyclophosphamide in the induction treatment for lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

First appearance and location of catecholaminergic cells during experimental arthritis and elimination by chemical sympathectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Clinical trials in lupus: what have we learned so far?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Immunomodulatory functions of type I interferons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Increased levels of NF-ATc2 differentially regulate CD154 and IL-2 genes in T cells from patients with systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

FTY720-induced conversion of conventional Foxp3- CD4+ T cells to Foxp3+ regulatory T cells in NOD mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Selective modulation of CD4+ T cells from lupus patients by a promiscuous, protective peptide analog

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Cytokines as therapeutic targets in SLE.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Connective tissue diseases: What does the death of Riquent hold for the future of SLE?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

JAK2 inhibition in murine systemic lupus erythematosus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.145

An update on belimumab for the treatment of lupus

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24100460

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24100460

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Unmasking of anti-ribosomal P autoantibodies in healthy individuals.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24100460

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRRHEUM.2013.145

1 reference

PubMed ID

24100460

Dimensions Publication ID

29 August 2017

0 references

1 reference

PubMed ID

24100460